[go: up one dir, main page]

HRPK20110080B3 - Composition for treatment of skeletal and joint disorders - Google Patents

Composition for treatment of skeletal and joint disorders

Info

Publication number
HRPK20110080B3
HRPK20110080B3 HRP20110080AA HRP20110080A HRPK20110080B3 HR PK20110080 B3 HRPK20110080 B3 HR PK20110080B3 HR P20110080A A HRP20110080A A HR P20110080AA HR P20110080 A HRP20110080 A HR P20110080A HR PK20110080 B3 HRPK20110080 B3 HR PK20110080B3
Authority
HR
Croatia
Prior art keywords
treatment
extract
composition
preparation
resin extract
Prior art date
Application number
HRP20110080AA
Other languages
Croatian (hr)
Inventor
Zdravko MAUKO
Original Assignee
Zdravko MAUKO
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zdravko MAUKO filed Critical Zdravko MAUKO
Priority to HRP20110080AA priority Critical patent/HRPK20110080B3/en
Priority to PCT/HR2012/000002 priority patent/WO2012104663A1/en
Publication of HRP20110080A2 publication Critical patent/HRP20110080A2/en
Publication of HRPK20110080B3 publication Critical patent/HRPK20110080B3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/32Burseraceae (Frankincense family)
    • A61K36/324Boswellia, e.g. frankincense
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/32Burseraceae (Frankincense family)
    • A61K36/328Commiphora, e.g. mecca myrrh or balm of Gilead
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40Transferrins, e.g. lactoferrins, ovotransferrins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Pripravak za liječenje koštanih poremećaja i poremećaja zglobova sastoji se od smjese suhog ekstrakta smole tamjana, suhog ekstrakta smole smirne i suhog ekstrakta laktoferina. Sinergijska učinkovitost sastavnica ovog pripravka znatno je bolja od zbroja učinkovitosti njegovih pojedinačnih sastavnica. Najbolji rezultati liječenja koštanih poremećaja kao što su artritis i artroza postižu se pripravkom u kojemu su ekstrakt smole tamjana, ekstrakt smole smirne i ekstrakt laktoferina zastupljeni u približnim težinskim omjerima 2:2:1. Pripravak se uzima oralno u formi tableta ili kapsula.The preparation for the treatment of bone disorders and joint disorders consists of a mixture of a dry incense resin extract, a myrrh resin extract and a lactoferrin dry extract. The synergistic efficacy of the constituents of this preparation is significantly better than the sum of the efficacy of its individual constituents. Best results in the treatment of bone disorders such as arthritis and arthrosis are achieved with a composition in which incense resin extract, myrrh resin extract, and lactoferrin extract are presented in approximate weight ratios of 2: 2. The preparation is taken orally in the form of tablets or capsules.

HRP20110080AA 2011-02-02 2011-02-02 Composition for treatment of skeletal and joint disorders HRPK20110080B3 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
HRP20110080AA HRPK20110080B3 (en) 2011-02-02 2011-02-02 Composition for treatment of skeletal and joint disorders
PCT/HR2012/000002 WO2012104663A1 (en) 2011-02-02 2012-01-24 Composition for treatment of bone and joint disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HRP20110080AA HRPK20110080B3 (en) 2011-02-02 2011-02-02 Composition for treatment of skeletal and joint disorders

Publications (2)

Publication Number Publication Date
HRP20110080A2 HRP20110080A2 (en) 2012-08-31
HRPK20110080B3 true HRPK20110080B3 (en) 2014-01-03

Family

ID=46602108

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20110080AA HRPK20110080B3 (en) 2011-02-02 2011-02-02 Composition for treatment of skeletal and joint disorders

Country Status (2)

Country Link
HR (1) HRPK20110080B3 (en)
WO (1) WO2012104663A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104606585A (en) * 2015-02-13 2015-05-13 焦振华 Traditional Chinese medicine preparation for treating reactive osteoarthritis and preparation method thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0248534A (en) 1988-07-28 1990-02-19 Bio Serae Sa:Soc Method for compounding antibacterial composition and compounded antibacterial composition
JP3184923B2 (en) 1992-01-08 2001-07-09 ビオ セレ ラボラトワール エス ア Anti-rheumatic drug
WO2002085921A2 (en) * 2001-03-01 2002-10-31 Johann Jauch Simple method for the synthesis of boswellic acids and derivatives thereof
EP1952818A4 (en) 2005-10-27 2009-10-21 Sunstar Inc Inhibitor of osteoclast formation, composition for oral administration and prophylactic or therapeutic agent for bone disease comprising lactoferrin-containing liposome
CN100518763C (en) * 2006-09-01 2009-07-29 胡庆华 Chinese medicine for treating bone pain or anesthesia caused by cold and dampness
CN100502929C (en) * 2007-02-06 2009-06-24 程宝良 Nourishing and Nourishing Yin Zhubi Pills

Also Published As

Publication number Publication date
WO2012104663A1 (en) 2012-08-09
HRP20110080A2 (en) 2012-08-31

Similar Documents

Publication Publication Date Title
MX343687B (en) Tricyclic sulfonamide compounds and methods of making and using same.
PH12013502261A1 (en) Partially saturated tricyclic compounds and methods of making and using same
MX343688B (en) Tricyclic pyrazole sulfonamide compounds and methods of making and using same.
CL2013002210A1 (en) Prebiotic formulation for human consumption comprising 2'-fucosylactose, 3'-sialylactose and 6'-sialylactose, in which the amount by weight of 3'-sialylactose is at least as high as the amount of 2'-fucosylactose; and method to modulate or stimulate the proliferation of bifidobacteria in the human intestine.
MY196319A (en) Polycyclic TLR7/8 Antagonists and use Thereof in the Treatment of Immune Disorders
CO6680658A2 (en) Gpr 40 agonist
MX2014008705A (en) Tricyclic sulfone compounds and methods of making and using same.
EA201791702A1 (en) THERAPEUTIC TOOLS ON THE BASIS OF GLYCANS AND RELATED METHODS
MX2014008706A (en) Tricyclic sulfonamide compounds and methods of making and using same.
SG10201808104RA (en) Cenicriviroc for the treatment of fibrosis
MX339201B (en) Sulphonamide compounds and methods of making and using same.
CO6690805A2 (en) 6-amino-nicotinamides substituted as modular of kcnq2 / 3
MX2021015256A (en) MIXTURE OF PLANT EXTRACTS FOR USE IN THE PREVENTION AND/OR TREATMENT OF CHRONIC INFLAMMATORY INTESTINAL DISEASES.
SG10201806854XA (en) Compositions comprising 15-ohepa and methods of using the same
WO2016190683A8 (en) Composition for preventing and treating muscle diseases or improving muscular function, containing platycodon grandiflorum extract
MX2014004694A (en) Compositions.
CR20130602A (en) NEW COMPOUNDS AS INHIBITORS OF DIACILGLICEROL ACILTRANSFERASA
MA47080A (en) PREPARATION OF A DRY BIOMASS EXTRACT RICH IN POLYPHENOLS
MY171048A (en) Pharmaceutical composition for preventing or treating amyloid beta peptide-associated diseases or conditions
WO2013184879A3 (en) Pumpable fat compositions
HRPK20110080B3 (en) Composition for treatment of skeletal and joint disorders
WO2016195194A3 (en) Novel tlr2 antagonists
WO2015044961A3 (en) Pharmaceutical composition comprising capecitabine and cyclophosphamide
AR066936A1 (en) 3 - (2R - TETRAHYDROFURIL - METHYL) - 2 - THIOXANTINE. PHARMACEUTICAL COMPOSITIONS.
PH12017500743A1 (en) Tau protein production accelerator, and therapeutic or preventive agent and therapeutic or preventive food composition for diseases caused by tau protein deficiency

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AKOB Publication of a request for the grant of a patent not including a substantive examination of a patent application (a consensual patent)
PKB1 Consensual patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20190125

Year of fee payment: 9

ODRP Renewal fee for the maintenance of a patent

Payment date: 20200128

Year of fee payment: 10

PK10 Patent expired after termination of 10 years for consensual patent

Effective date: 20210202